8-K: CONMED Corporation Announces First Quarter 2025 Financial Results, Updates Full-Year Guidance

CONMED Corporation reports a 2.9% increase in first-quarter sales and updates its full-year revenue and adjusted diluted net earnings per share guidance.

Summary

• CONMED Corporation announced its financial results for the first quarter ended March 31, 2025.
• Sales for the quarter reached $321.3 million, a 2.9% increase year-over-year as reported, and a 3.8% increase in constant currency.
• Domestic revenue increased by 4.2% year-over-year, while international revenue increased by 1.2% as reported and 3.4% in constant currency.
• Diluted net earnings per share (GAAP) were $0.19, compared to $0.63 in the first quarter of 2024.
• Adjusted diluted net earnings per share were $0.95, compared to $0.79 in the first quarter of 2024.
• The company has updated its full-year revenue guidance to between $1.350 billion and $1.378 billion, compared to the prior range of $1.344 billion and $1.372 billion.
• Full-year adjusted diluted net earnings per share are now expected to be in the range of $4.45 to $4.60, compared to the prior range of $4.25 to $4.40.
• These updated guidance figures do not include the effects of recent tariff announcements, which are estimated to negatively impact EPS by approximately $0.14 in the second half of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to increased sales, improved adjusted earnings, and raised guidance, but tempered by a decrease in GAAP earnings and potential tariff impacts.

Positives

• Sales increased by 2.9% year-over-year, indicating growth in the business.
• Domestic revenue increased by 4.2%, showing strength in the domestic market.
• Adjusted diluted net earnings per share increased from $0.79 to $0.95, reflecting improved profitability.
• The company raised its full-year revenue and adjusted diluted net earnings per share guidance.
• The company expects reduced currency headwinds compared to previous expectations.

Negatives

• Diluted net earnings per share (GAAP) decreased from $0.63 to $0.19, indicating a decline in GAAP profitability.
• Tariff announcements are expected to negatively impact EPS by approximately $0.14 in the second half of 2025.

Risks

• The company acknowledges that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.
• Recent tariff announcements are expected to negatively impact EPS by approximately $0.14 in the second half of 2025.
• The company's performance is subject to general industry and economic conditions.

Future Outlook

The company expects full-year revenue to be between $1.350 billion and $1.378 billion and adjusted diluted net earnings per share to be in the range of $4.45 to $4.60. This updated guidance does not include the effects of recent tariff announcements, which the Company estimates would result in a negative impact to EPS of approximately $0.14 in the second half of 2025.

Management Comments

• Patrick J. Beyer, CONMED's President and Chief Executive Officer, stated that the company had a good start to 2025, positioning them well to achieve their full-year guidance.
• Beyer also expressed pride in the team's dedication to strengthening operations to better support key growth platforms and drive long-term shareholder value.

Industry Context

CONMED's results reflect the ongoing trends in the medical technology industry, including a focus on surgical procedures and the impact of currency exchange rates and tariffs on international sales and profitability. The company's focus on key growth platforms aligns with the industry's emphasis on innovation and market expansion.

Comparison to Industry Standards

• Comparing CONMED's 2.9% revenue growth to competitors like Stryker (SYK) or Johnson & Johnson (JNJ) in their medical device segments would provide a benchmark for performance.
• Medtronic (MDT) and Boston Scientific (BSX) are also key players whose growth rates and profitability metrics could be used for comparison.
• CONMED's adjusted diluted EPS of $0.95 can be compared to the EPS growth of these companies to assess its relative profitability.
• The updated full-year revenue guidance of $1.350 billion to $1.378 billion should be evaluated against the revenue forecasts and actual results of similar-sized medical device companies.

Stakeholder Impact

• Shareholders can expect increased value due to the company's growth and improved profitability.
• Employees may benefit from the company's strengthened operations and focus on key growth platforms.
• Customers can expect continued access to CONMED's devices and equipment for surgical procedures.

Next Steps

• The company will host a conference call at 4:30 p.m. ET on April 30, 2025, to discuss the first quarter 2025 results.
• Investors can access the webcast replay of the call on CONMED's website.

Key Dates

Keywords

financial results, CONMED, earnings, revenue, guidance, medical technology, orthopedic surgery, general surgery